Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07562789

Role of PCGEM1 in Breast Cancer

This study examines certain molecular markers in breast cancer using blood and tissue samples from routine diagnostic biopsies. No extra procedures will be performed on patients. The goal is to improve understanding of disease mechanisms and identify potential targets for treatment

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

About this study

This is an observational, case-control study designed to evaluate the expression of lncRNA PCGEM1 and its association with related molecular pathways, including RhoA, TRIAP1, and ferroptosis, in breast cancer patients. The study will include patients diagnosed with breast cancer and a matched control group.

No intervention will be performed as part of this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care, with no additional procedures carried out for research purposes.

Collected tissue samples will be processed for RNA extraction and subsequent molecular analysis to assess gene expression levels. The results will be analyzed to explore the potential role of PCGEM1 in tumor progression and its correlation with selected molecular pathways.

The findings of this study may contribute to a better understanding of breast cancer biology and help identify potential biomarkers or therapeutic targets.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18 years and older.
  • Newly diagnosed patients with histopathological confirmation of the diagnosis of breast cancer at any stage.

Exclusion criteria

  • Presence of any chronic diseases.
  • Previous history of breast cancer or other malignancies.
  • Evidence of distant metastasis at the time of diagnosis.
  • Prior treatment with chemotherapy or radiotherapy.
  • Incomplete clinical or laboratory data.

Treatment and study plan

No Biologics

Device

No intervention will be performed in this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care

Primary outcomes

  1. Relative expression level of PCGEM1 marker in breast cancer tissue and blood sample

    Time frame: at base line

    This outcome measures the relative expression level of PCGEM1 in breast cancer tissue and blood samples compared to control using quantitative real-time PCR (qRT-PCR). The results will be correlated with clinicopathological parameters.

Study contacts

Contact information is provided by the study sponsor or research team.

Rehab M Ahmed

CONTACT

[email protected]

00201003804148

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Long Non-coding RNA: PCGEM1 as a Potential Marker for Tumorigenesis in Breast Cancer

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 1, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.